Equities research analysts expect that Obalon Therptcs (NASDAQ:OBLN) will announce ($0.43) earnings per share for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Obalon Therptcs’ earnings. The highest EPS estimate is ($0.39) and the lowest is ($0.47). The business is expected to report its next quarterly earnings results on Wednesday, August 9th.

According to Zacks, analysts expect that Obalon Therptcs will report full year earnings of ($1.82) per share for the current financial year, with EPS estimates ranging from ($1.86) to ($1.77). For the next year, analysts anticipate that the firm will post earnings of ($1.64) per share, with EPS estimates ranging from ($1.65) to ($1.64). Zacks’ earnings per share averages are a mean average based on a survey of analysts that follow Obalon Therptcs.

Obalon Therptcs (NASDAQ:OBLN) last posted its earnings results on Wednesday, May 10th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by $0.14. The business had revenue of $1.47 million during the quarter, compared to analysts’ expectations of $1.60 million.

A number of analysts recently commented on the company. Northland Securities assumed coverage on Obalon Therptcs in a research report on Wednesday, June 21st. They issued an “under perform” rating and a $6.00 target price for the company. BTIG Research reaffirmed a “buy” rating and issued a $20.00 target price on shares of Obalon Therptcs in a research report on Sunday, March 19th. ValuEngine raised Obalon Therptcs from a “strong sell” rating to a “sell” rating in a research report on Friday, June 2nd. Zacks Investment Research downgraded Obalon Therptcs from a “buy” rating to a “hold” rating in a research note on Wednesday, April 26th. Finally, Canaccord Genuity reiterated a “buy” rating on shares of Obalon Therptcs in a research note on Thursday, May 18th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $14.20.

Obalon Therptcs (NASDAQ:OBLN) opened at 8.90 on Friday. Obalon Therptcs has a 1-year low of $8.27 and a 1-year high of $15.88. The firm has a 50-day moving average price of $10.30 and a 200-day moving average price of $10.06. The firm’s market capitalization is $149.45 million.

WARNING: “Obalon Therptcs (NASDAQ:OBLN) Expected to Announce Earnings of -$0.43 Per Share” was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another domain, it was copied illegally and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/07/07/obalon-therptcs-nasdaqobln-expected-to-announce-earnings-of-0-43-per-share.html.

A number of institutional investors have recently added to or reduced their stakes in OBLN. Neuburgh Advisers LLC bought a new position in Obalon Therptcs during the first quarter worth about $310,000. Meadow Creek Investment Management LLC acquired a new position in shares of Obalon Therptcs during the first quarter worth $659,000. Handelsbanken Fonder AB increased its position in shares of Obalon Therptcs by 200.0% in the first quarter. Handelsbanken Fonder AB now owns 60,000 shares of the company’s stock worth $641,000 after buying an additional 40,000 shares during the last quarter. Bank of New York Mellon Corp acquired a new position in shares of Obalon Therptcs during the first quarter worth $168,000. Finally, Elkfork Partners LLC acquired a new position in shares of Obalon Therptcs during the first quarter worth $543,000. Institutional investors and hedge funds own 61.63% of the company’s stock.

Obalon Therptcs Company Profile

Obalon Therapeutics, Inc is a United States-based commercial-stage medical device company focused on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss. The Company’s product, Obalon balloon system, is a swallowable, gas-filled intragastric balloon designed to provide weight loss in obese patients.

Get a free copy of the Zacks research report on Obalon Therptcs (OBLN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Obalon Therptcs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obalon Therptcs and related companies with MarketBeat.com's FREE daily email newsletter.